35.48
-0.64 (-1.77%)
| Penutupan Terdahulu | 36.12 |
| Jumlah Dagangan | 181,185 |
| Harga / Jualan (P/S) | 438.73 |
| Harga / Buku (P/B) | 3.27 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -9,701.19% |
| EPS Cair (TTM) | -4.36 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 4.01% |
| Nisbah Semasa (MRQ) | 21.03 |
| Aliran Tunai Operasi (OCF TTM) | -69.73 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -40.39 M |
| Pulangan Atas Aset (ROA TTM) | -21.97% |
| Pulangan Atas Ekuiti (ROE TTM) | -34.96% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Neurogene Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | -1.5 |
| Osilator Teknikal | -0.5 |
| Purata | -2.17 |
|
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 9.28% |
| % Dimiliki oleh Institusi | 115.82% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Casdin Capital, Llc | 30 Jun 2026 | 1,545,361 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |